- Health Spotlight's Scleroderma Insights
- Posts
- Weekly Spotlight - 12.12.24
Weekly Spotlight - 12.12.24
Late-Onset ILD in Scleroderma: A Call for Continued Vigilance
Liam Ball
December 12, 2024 • Estimated Reading Time: 4 minutes
Community |
Your journey can be a beacon of hope and a source of strength for others in our community. Together, we can build a stronger, more supportive community. Your story matters, and it deserves to be heard. Fill in this form to be featured. |
Latest News
Late-onset interstitial lung disease (ILD) in scleroderma patients can occur years after initial symptoms, with similar severity and progression to early-onset cases. Continuous monitoring is crucial, as risk factors remain consistent. This study highlights the need for vigilance in managing scleroderma, offering hope through effective treatments.
The study explores frailty in systemic sclerosis patients, using the FRAIL Scale to categorise participants as robust pre-frail or frail. Annual assessments reveal frailty progression, with determinants analysed through logistic regression. Survival rates are examined via Cox hazard modelling, offering insights into patient care and management.
EULAR new recommendations for systemic sclerosis highlight advances in treatment, particularly for skin and lung fibrosis. The focus is on combination therapies and avoiding warfarin in SSc-PAH. A research agenda aims to explore immune suppression and cardiovascular effects, offering hope for improved patient outcomes.
The article exposes five medications deemed scams by a pharmacist, aiming to protect consumers. It highlights the importance of being informed about ineffective treatments. The pharmacist insights offer reassurance, encouraging individuals to seek reliable medical advice and make informed health decisions, fostering a supportive community of well-informed patients.
Health Spotlight’s Systemic Sclerosis is a Contentive publication in the Healthcare division